Select Language
CD38
CD38 Overview
| English Name | Lymphocyte differentiation antigen CD38 | Approved Drugs | 3 |
| Drugs in Clinical Trials | 44 | Target Synonym | EC:3.2.2.6，EC:2.4.99.20，2-Phospho-Cyclic-ADP-Ribose Transferase，Cyclic ADP-Ribose Hydrolase 1，2-Phospho-ADP-Ribosyl Cyclase，NAD(+) Nucleosidase，CD38 Antigen (P45)，2-Phospho-ADP-Ribosyl Cyclase/2-Phospho-Cyclic-ADP-Ribose Transferase，Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase，ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1，Cluster Of Differentiation 38，CD38 Antigen，EC 2.4.99.20，EC 3.2.2.6，ADPRC1，T10，2'-phospho-ADP-ribosyl cyclase，ADPRC 1，cADPr hydrolase 1，ADP-ribosyl cyclase 1，2'-phospho-cyclic-ADP-ribose transferase，CD38，CD38 Molecule，2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase |
| Highest Development Stage | Approved | ||
| English Name | Lymphocyte differentiation antigen CD38 |
| Target Synonym | EC:3.2.2.6，EC:2.4.99.20，2-Phospho-Cyclic-ADP-Ribose Transferase，Cyclic ADP-Ribose Hydrolase 1，2-Phospho-ADP-Ribosyl Cyclase，NAD(+) Nucleosidase，CD38 Antigen (P45)，2-Phospho-ADP-Ribosyl Cyclase/2-Phospho-Cyclic-ADP-Ribose Transferase，Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase，ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1，Cluster Of Differentiation 38，CD38 Antigen，EC 2.4.99.20，EC 3.2.2.6，ADPRC1，T10，2'-phospho-ADP-ribosyl cyclase，ADPRC 1，cADPr hydrolase 1，ADP-ribosyl cyclase 1，2'-phospho-cyclic-ADP-ribose transferase，CD38，CD38 Molecule，2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 44 |
| Highest Development Stage | Approved |
CD38 Product List
- Product Category
Protein (10)Beads (1)Antibody (1)Kits (1)
- Product Status
Launched (13)
- Species
Human (10)Cynomolgus (1)Mouse (1)Rabbit (1)
- Tag
His Tag (4)His Tag & Avi Tag (1)Fc Tag (2)Mouse IgG Fc Tag (1)- (3)Fc Tag & Avi Tag (1)Avi Tag (1)
- Conjugate
Unconjugated (6)Biotin-labeled (3)- (2)FITC Labeled (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT CD8-H5224 |  Human | HEK293 | Human CD38 Protein, His Tag (MALS verified) |  |  |  |  Add to Cart |
HOT CD8-H5255 | Human | HEK293 | Human CD38 Protein, Fc Tag (MALS verified) |  | | | Add to Cart |
HOT CD8-H82E7 | Human | HEK293 | Biotinylated Human CD38 Protein, Avitag™,His Tag (MALS verified) |  | | | Add to Cart |
HOT CD8-HF2H5 | Human | HEK293 | FITC-Labeled Human CD38 Protein, His Tag (MALS verified) |  | | | Add to Cart |
CD8-H5253 | Human | HEK293 | Human CD38 Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | | Add to Cart |
CD8-H8214 | Human | HEK293 | Biotinylated Human CD38 Protein, Avitag™ |  | | | Add to Cart |
CD8-H82F5 | Human | HEK293 | Biotinylated Human CD38 Protein, Fc,Avitag™ (MALS verified) |  | | | Add to Cart |
CD8-HF255 | Human | HEK293 | FITC-Labeled Human CD38 Protein, Fc Tag |  | | | Add to Cart |
CEA-B039 | Human | - | Human Soluble CD38 ELISA Kit | Add to Cart | |||
MBC-K010 | Human | - | Human CD38-coupled Magnetic Beads | Add to Cart |
Total: 13
- 1
- 2
CD38 Background
CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.
CD38 Synonyms
CD38,T10,cADPr hydrolase 1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mezagitamab | TAK-079 | Phase 3 Clinical | Takeda Pharmaceutical Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Hematologic Neoplasms; Myasthenia Gravis; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis | Details |
| Daratumumab biosimilar (Biocad) | BCD-264 | Phase 3 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 3 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Neoplasms; Multiple Myeloma; Melanoma | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
| REGN-7945 | REGN7945; REGN-7945 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| SCTC-21-C | SCTC21C; SCTC-21-C; SCT-C21C | Phase 2 Clinical | SinoCelltech Ltd | Hematologic Neoplasms; Glomerulonephritis, IGA; Autoimmune Diseases | Details |
| Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome; Thrombocytopenia | Details | |
| Erzotabart | GEN-3014 | Phase 2 Clinical | Genmab A/S | Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| CID-103 | CID-103; TSK011010 | Phase 2 Clinical | Tusk Therapeutics Ltd | Purpura, Thrombocytopenic, Idiopathic; Multiple Myeloma; Thrombocytopenia | Details |
| BHV-1100 | KP-1237; BHV-1100 | Phase 2 Clinical | PeptiDream Inc, Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals | Multiple Myeloma | Details |
| Lumrotatug | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Hematologic Neoplasms; Glomerulonephritis, IGA; Anemia; Blood Platelet Disorders; Multiple Myeloma; Lupus Erythematosus, Systemic; Anemia, Aplastic; Lymphoma; Thrombocytopenia | Details |
| 89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| 64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| dual anti-BCMA/anti-CD38 CAR T-cell therapy (Shengyan Pharmaceutical Technology/Tongji Medical College) | Phase 1 Clinical | Tongji Medical College | Multiple Myeloma | Details | |
| CD38 CAR T-cells | Phase 1 Clinical | Zhejiang University | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| anti-CD38 CAR T-cell therapy (Shanghai Unicar-Therapy Bio-Medicine Technology/Soochow University/East China Normal University) | Phase 1 Clinical | Soochow University | Leukemia, Myeloid, Acute | Details | |
| T-007 (TNK Therapeutics/Celularity) | Phase 1 Clinical | Tnk Therapeutics Inc | Multiple Myeloma | Details | |
| Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| CD38\CS1 Chimeric Antigen Receptor T Cells therapy(The Second Hospital Of Shandong University) | Phase 1 Clinical | The Second Hospital Of Shandong University | Multiple Myeloma | Details | |
| SAR-444559 | SAR444559; SAR-444559 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| 68Ga-NB-381 | 68Ga-NB381; 68Ga-NB-381; 18F-FDG(The First Affiliated Hospital Of Beijing University) | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Multiple Myeloma | Details |
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD38-SADA:177 Lu-DOTA Drug Complex | Phase 1 Clinical | Y-Mabs Therapeutics Inc | Lymphoma, Non-Hodgkin | Details | |
| RB-0021 | RB0021; RB-0021 | Phase 1 Clinical | Ruiyang (Suzhou) Biological Technology Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) | Phase 1 Clinical | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | Multiple Myeloma | Details | |
| KYS202002A | KYS-202002A; KYS202002A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| Daratumumab biosimilar (Chiatai Tianqing) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| CART-38（University of Pennsylvania） | CART-38 | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| ISB-2001 | ISB-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| TNB-738 | TNB-738 | Phase 1 Clinical | TeneoFour Inc | Details | |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| Daratumumab biosimilar (Henlius) | HLX-15 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Multiple Myeloma | Details |
| 211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details | |
| SAR-442085 | SAR-442085 | Phase 1 Clinical | Sanofi | Multiple Myeloma | Details |
| KJ-C2320 | KJ-C2320 | Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Myeloid, Acute | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab/Hyaluronidase-fihj | Approved | Johnson & Johnson Innovative Medicine | Darzalex Faspro, Darzquro | United States | Multiple Myeloma | Janssen Biotech Inc | 2020-05-01 | Monoclonal Gammopathy of Undetermined Significance; Rejection in heart transplantation; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Amyloidosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Multiple Myeloma; Myelodysplastic Syndromes; Hodgkin Disease; Smoldering Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Peripheral Nervous System Diseases; Leukemia, Myelogenous, Chronic; Bone marrow transplant rejection | Details | |
| Isatuximab | SAR-650984; hu38SB19 | Approved | Immunogen Inc | Sarclisa | United States | Multiple Myeloma | Sanofi-Aventis U.S. Llc | 2020-03-02 | Satiety Response; Carcinoma, Non-Small-Cell Lung; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Macroglossia; Leukemia, Myeloid, Acute; Nausea; Amyloidosis; Hepatomegaly; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Gastrointestinal Hemorrhage; Diarrhea; Prostatic Neoplasms; Goiter, Nodular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Hodgkin Disease; Neoplasms; Purpura; Immunoglobulin Light-chain Amyloidosis; Smoldering Multiple Myeloma; Leukemia, Plasma Cell; Lymphadenopathy; Paraproteinemias; Hematologic Neoplasms; Constipation | Details |
| Daratumumab | JNJ-54767414 | Approved | Johnson & Johnson Innovative Medicine | Darzalex, 兆珂速, 兆珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2015-11-16 | Rejection of organ transplantation; Hypersensitivity; POEMS Syndrome; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Alzheimer Disease; Urologic Neoplasms; Amyloidosis; Lymphoma, Primary Effusion; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Prostatic Neoplasms; Kidney Neoplasms; Multiple Myeloma; Carcinoma, Transitional Cell; Autoimmune Diseases; Hodgkin Disease; Glioblastoma; Immunoglobulin Light-chain Amyloidosis; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Paraproteinemias; Genital Neoplasms, Male; Purpura, Thrombocytopenic, Idiopathic; Rejection of renal transplantation | Details |
Product Reviews
Y***u2023-03-31
0People LikeThis product can be used at < 0.4 ug/ml as a detection agent to quantify anti CD38 antibodies in a binding assay. Anti CD38 antibodies in either bovine serum albumin based sample diluent or murine serum can be detected by this production without a problem. Specific signals from the subsequent streptavidin conjugated enzyme reaction were very strong and very low noise from the negative control antibody group.- Y***u2023-03-16 0People LikeUsed 3 ug/ml of this protein as the capture antigen in an ELISA assay to screen for anti-mouse CD38 mAbs. Very strong signal from the positive control anti-mouse CD38 mAb (clone: NIMR5) and no binding to several anti-human CD38 mAbs or the anti-IgG secondary Ab in the assay. The "ETD of in-stock products: 2 business days" statement on Acro website was accurate. Fast shipment. Professional COA and instructions on how to reconstitute and store this product.
- 1***02019-10-11 0People LikeI bought a lot of products. This protein has high purity and good bioactivity. Whether it is for ELISA or functional assay, all went smoothly. The price is favorable and the service is also good. I support and recommend ACRO! Go ACRO!
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland